| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825629 | Clinical Therapeutics | 2013 | 14 Pages |
Abstract
Except for Q4 within the vancomycin-treated patients for MRSA cSSSI, the efficacy of fixed-dosed linezolid and weight-based dosing of vancomycin was maintained across all weight quartiles and MRSA infection types. The AEs were consistent with the known safety profiles of each drug regardless of weight quartile. ClinicalTrials.gov identifiers: NCT00087490 and NCT00084266.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Laura A. PhD, MPH, Lee E. MD, David B. MD, PhD, Jason N. PharmD,